Analytical Data
-
Gene name
MIG7
- Application
-
Alternative Names
/
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q1AHR6
-
Expression Region
1-207aa
-
Molecular Weight
35.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MIG7, also known as the "mitogen-inducible gene 7," is a member of the early response genes that are rapidly activated upon mitogenic stimulation in various cell types. Its role has garnered attention in the fields of cancer research and immunology due to its potential involvement in cellular proliferation, differentiation, and apoptosis. Studies have suggested that MIG7 may be linked to key signaling pathways that are often dysregulated in cancer, particularly those involving the MAPK pathway. Additionally, MIG7 has been implicated in immune responses, influencing the behavior of various immune cells. Research into MIG7 recombinant proteins aims to elucidate its functional mechanisms and explore its potential as a biomarker for tumor progression or as a therapeutic target. The generation of MIG7 recombinant proteins allows for detailed biochemical studies, including protein-protein interactions and effects on signaling pathways. By better understanding MIG7's role in cellular processes, researchers hope to identify novel strategies for cancer treatment and enhance the therapeutic efficacy of existing approaches. Furthermore, the investigation of MIG7 can also provide insights into immune modulation, making it a relevant target for developing innovative immunotherapies. Overall, the study of MIG7 and its recombinant proteins holds promise for advancing our understanding of tumor biology and improving therapeutic strategies against cancer and other diseases.
